Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
Mosunetuzumab plus polatuzumab vedotin achieved high CR rates in relapsed or refractory MCL with prior BTKi treatment.
Interspersing cytarabine in R-CHOP induction therapy did not yield significant improvements in elderly patients with MCL.
BOVen induced high rates of response and MRD-negativity among patients with untreated MCL with TP53 mutations.
The study established the recommended phase II dose of ibrutinib combined with bortezomib.
Analysis of MCL tissue identified a immune-depleted tumor microenvironment subtype associated with treatment resistance.
Brexu-cel was associated with improved OS compared with the standard of care (SOC) regimens, including bendamustine plus ...
Advertisement
The practice of medicine, in many ways, can cycle like the seasons do.
The investigators conceded the longer follow-up is needed but the results are promising.
RNA sequencing analysis revealed noncanonical function of BACH1 in regulation of type I interferon response.
The four-center, open-label, single-arm study included 38 patients with untreated MCL.
The trial was a part of an extension study that included a longer follow-up compared with two previous trials.
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Brexucabtagene autoleucel is a promising therapy in relapsed or refractory MCL.
Pirtobrutinib can be safely used along with concomitant antithrombotic therapy (CAT) in treating B-cell malignancies.
The overall response rate was 83.8% and the CR rate was 73% after the median follow-up of eight months.
A first-line induction regimen that alternates VR-CAP with R-DHAP can improve treatment response in newly diagnosed MCL.
The patient cohort had median OS of 27 months and a five-year OS of 24.5%.
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.